Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 3/20 | 0.46 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.40 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191106 | 0.98 | CYP11B1 (0.55) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| SCHEMBL1190878 | 0.84 | CYP11B1 (0.58) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| SCHEMBL7328231 | 0.81 | CYP11B1 (0.40) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| SCHEMBL5214057 | 0.74 | ALDH1A1 (0.60) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| Hydrochloric Acid SCHEMBL30293243 | 0.74 | MMP12 (0.56) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| Hydrochloric Acid SCHEMBL6518631 | 0.74 | MMP12 (0.56) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| SCHEMBL30494187 | 0.73 | NR3C2 (0.55) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| SCHEMBL26463277 | 0.73 | NR3C2 (0.55) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| SCHEMBL21004232 | 0.73 | MMP12 (0.44) | CYP11B1CYP11B2MMP12PARP1NR3C2 | |
| SCHEMBL10552765 | 0.72 | CYP11B1 (0.40) | CYP11B1CYP11B2MMP12NR3C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070923-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | JW PHARMACEUTICAL CORP (KR) | 2026-03-12 | — | — | US | disclosed |
| US-12497410-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2025-12-16 | — | — | US | disclosed |
| CN-119143779-A | Process for preparing heterocyclic derivative compounds, compositions containing the compounds and hydrates of the compounds | JW 制药公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3909956-B1 | HYDROCHLORIDE SALT 1.5 HYDRATE OF AN HETEROCYCLIC DERIVATIVE COMPOUND | JW PHARMACEUTICAL CORP (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-12103938-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-10-01 | — | — | US | disclosed |
| CN-114085235-B | Process for preparing heterocyclic derivative compounds, compositions containing the compounds and hydrates of the compounds | JW 制药公司 | 2024-08-13 | — | — | CN | disclosed |
| US-12030895-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240083911-A1 | Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-03-14 | — | — | US | disclosed |
| US-20240067659-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | JW PHARMACEUTICAL CORPORATION (KR) | 2024-02-29 | — | — | US | disclosed |
| US-11866448-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | JW PHARMACEUTICAL CORPORATION (KR) | 2024-01-09 | — | — | US | disclosed |
| US-20220363691-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | JW PHARMACEUTICAL CORPORATION (KR) | 2022-11-17 | — | — | US | disclosed |
| US-20220340594-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | JW PHARMACEUTICAL CORPORATION (KR) | 2022-10-27 | — | — | US | disclosed |
| EP-3909955-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A HETEROCYCLIC DERIVATIVE FOR USE IN THE TREATMENT OF HYPERURICEMIA | JW Pharmaceutical Corporation (KR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909956-A1 | HYDROCHLORIDE SALT 1.5 HYDRATE OF AN HETEROCYCLIC DERIVATIVE COMPOUND | JW Pharmaceutical Corporation (KR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3632917-B1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE | JW PHARMACEUTICAL CORP (KR) | 2021-11-17 | — | — | EP | disclosed |
| US-20200207784-A1 | Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound | JW PHARMACEUTICAL CORPORATION (KR) | 2020-07-02 | — | — | US | disclosed |
| EP-3632917-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | JW Pharmaceutical Corporation (KR) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363691-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-20240083911-A1 | Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-12103938-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-20260070923-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | SLC26A3, SLC10A6, SLC14A1 | PARP1 3709/4885PDE3B 2540/4885PDE3A 2307/4885 |
| US-20200207784-A1 | Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-20220340594-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-11866448-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-20240067659-A1 | METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-12497410-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
| US-12030895-B2 | Method for preparing heterocyclic derivative compound, composition containing same compound, and hydrate of same compound | REN, NOD1, NLRP3 | PARP1 4501/4885PDE3B 747/4885PDE3A 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.